Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Raloxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | PLD2 | O14939 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | C5 | P01031 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raloxifene SCHEMBL6144 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL29362592 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL9145135 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL5821250 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9201404 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL1665344 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL1665291 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL7630144 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL12485521 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL973873 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-2245052-A2 | SELECTIVE EXOSITE INHIBITION OF PAPP-A ACTIVITY AGAINST IGFBP-4 | Aarhus Universitet (DK) | 2010-11-03 | — | — | EP | disclosed |
| EP-2167076-A2 | HYDROXYPROLINE COMPOSITIONS AND USES THEREOF | Bergen Teknologioverforing AS (NO) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009092806-A2 | SELECTIVE EXOSITE INHIBITION OF PAPP-A ACTIVITY AGAINST IGFBP-4 | AARHUS UNIVERSITET (DK) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008148873-A2 | HYDROXYPROLINE COMPOSITIONS AND USES THEREOF | BERGEN TEKNOLOGIOVERFØRING AS (NO) | 2008-12-11 | — | — | WO | disclosed |
| CN-1184895-C | Soybean composition and application thereof for promoting health | TABOR AARON (US) | 2005-01-19 | — | — | CN | disclosed |
| CN-1277540-A | Soybean formula and application thereof in health promotion | AARON TABOR (US) | 2000-12-20 | — | — | CN | disclosed |
| EP-0777476-A4 | METHODS OF INHIBITING ENDOMETRIAL CANCER | LILLY CO ELI (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0782446-A4 | METHODS OF INHIBITING ENDOMETRIAL MITOSES | LILLY CO ELI (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5843964-A | Methods of inhibiting endometrial mitoses | ELI LILLY AND COMPANY (US) | 1998-12-01 | — | — | US | disclosed |
| US-5747510-A | 2-HYDROXYPHENYL-3-/P-/2-MORPHOLINOETHOXY/BENZOYL/-6-HYDROXY-BE NZOTHIOPHENE, INHIBITING BONE LOSS, LOWERING SERUM CHOLESTEROL | ELI LILLY AND COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0782446-A1 | METHODS OF INHIBITING ENDOMETRIAL MITOSES | ELI LILLY AND COMPANY (US) | 1997-07-09 | — | — | EP | disclosed |
| US-5641790-A | PHARMACEUTICAL FORMULATION IN LOW DOSAGE UNIT FORM CONTAINING 2-PHENYL-3-AROYLBENZOTHIOPHENE DERIVATIVE | ELI LILLY AND COMPANY (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0777476-A1 | METHODS OF INHIBITING ENDOMETRIAL CANCER | ELI LILLY AND COMPANY (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5610168-A | ADMINISTERING RALOXIFENE, A BENZOTHIOPHENE DERIVATIVE, TREATMENT OF OSTEOPOROSIS | ELI LILLY AND COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996009050-A1 | METHODS OF INHIBITING ENDOMETRIAL MITOSES | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| WO-1996005833-A1 | METHODS OF INHIBITING ENDOMETRIAL CANCER | ELI LILLY AND COMPANY (US) | 1996-02-29 | — | — | WO | disclosed |